Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders – A retrospective cohort study in Taiwan

Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders – A retrospective cohort study in Taiwan

Background: Active tuberculosis (TB) in patients with latent tuberculosis infection (LTBI) was associated with use of biological agents for immune-mediated inflammatory disorders (IMIDs). For decreasing active TB, isoniazid prophylaxis therapy was administered before biologic therapy among IMID pati...

Full description

Bibliographic Details
Main Authors:	Shiang-Fen Huang, Ming-Han Chen, Fu-Der Wang, Chang-Youh Tsai, Chang-Phone Fung, Wei-Juin Su
Format:	Article
Language:	English
Published:	Elsevier 2018-12-01
Series:	Journal of Microbiology, Immunology and Infection
Online Access:	http://www.sciencedirect.com/science/article/pii/S1684118217301044

Similar Items

Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan.
by: Tsai-Ling Liao, et al.
Published: (2016-01-01)

Isoniazid-Resistant Tuberculosis, Taiwan, 2000–2010
by: Chih-Cheng Lai, et al.
Published: (2011-09-01)

Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study
by: Denholm JT, et al.
Published: (2014-10-01)

Factors associated with failure to complete isoniazid therapy for latent tuberculosis infection in children and adolescents
by: Shiow-Huey Chang, et al.
Published: (2014-03-01)

Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection
by: Weeraya Phaisal, et al.
Published: (2022-09-01)

Short-course isoniazid plus rifapentine therapy for latent tuberculosis in Brazil
by: Julio Croda
Published: (2015-10-01)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
by: Ghassan Ilaiwy, et al.
Published: (2021-08-01)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
by: Wendy A. Lai, et al.
Published: (2022-12-01)

Scaling up of latent tuberculosis infection treatment for close contacts of tuberculosis in Taiwan
by: Pei-Chun Chan, et al.
Published: (2011-12-01)

A retrospective cohort study of isoniazid-resistant tuberculosis treatment outcomes and isoniazid resistance-associated mutations in eastern China from 2013 to 2018
by: Yan Shao, et al.
Published: (2020-09-01)

Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review
by: Bárbara Manuella Cardoso Sodré-Alves, et al.
Published: (2024-03-01)

Characteristics of <it>pncA </it>mutations in multidrug-resistant tuberculosis in Taiwan
by: Lee Yu-Chin, et al.
Published: (2011-09-01)

Determinants of latent tuberculosis infection and treatment interruption in long-term care facilities: A retrospective cohort study in Taiwan
by: Ting-Fang Chiu, et al.
Published: (2022-12-01)

It is Time to Deal With Latent Tuberculosis Infection in Taiwan
by: Pei-Chun Chan, et al.
Published: (2009-12-01)

A retrospective cohort study on the treatment outcomes and genotyping of isoniazid-resistant tuberculosis patients in Eastern China
by: Yishu Li, et al.
Published: (2022-09-01)

Acquired Resistance to Isoniazid During Isoniazid Monotherapy in a Subject with Latent Infection Following Household Rifampicin-Resistant Tuberculosis Contact: A Case Report
by: Li TL, et al.
Published: (2021-04-01)

Safety and treatment completion of latent tuberculosis infection treatment in the elderly population—A prospective observational study in Taiwan
by: Jia-Yih Feng, et al.
Published: (2020-07-01)

ISONIAZID - MONORESISTANT TUBERCULOSIS IN BULGARIA
by: Stanislava Yordanova, et al.
Published: (2020-05-01)

Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis
by: I Frésard, et al.
Published: (2011-08-01)

Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events
by: Shang-Yi Lin, et al.
Published: (2019-02-01)

Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness.
by: Nwabunie Nwana, et al.
Published: (2019-01-01)

Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus
by: Shiang-Fen Huang, et al.
Published: (2017-10-01)

Electrospun Orodispersible Films of Isoniazid for Pediatric Tuberculosis Treatment
by: Konstantina Chachlioutaki, et al.
Published: (2020-05-01)

Gender disparities in latent tuberculosis infection in high-risk individuals: a cross-sectional study.
by: Wen-Ying Ting, et al.
Published: (2014-01-01)

Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis.
by: Raymund Dantes, et al.
Published: (2012-01-01)

Treatment of isoniazid-resistant pulmonary tuberculosis
by: Lim Si, et al.
Published: (2008-01-01)

Isoniazid, The Frontline of Resistance in Mycobacterium tuberculosis
by: James B. Whitney, et al.
Published: (2002-12-01)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
by: Byung Woo Jhun, M.D., et al.
Published: (2020-01-01)

Combination of Isoniazid and Rifampin for the Prevention of Failure of Standard Therapy for Latent Tuberculosis Infection in Children: Evidence Base Case Report
by: Bakhtiar Bakhtiar, et al.
Published: (2021-10-01)

Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis.
by: Tsai-Yu Wang, et al.
Published: (2014-01-01)

Community-onset Klebsiella pneumoniae pneumonia in Taiwan: clinical features of the disease and associated microbiological characteristics of isolates from pneumonia and nasopharynx
by: Yi-Tsung eLin, et al.
Published: (2015-02-01)

Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia.
by: Muluwork Getahun, et al.
Published: (2022-01-01)

The tuberculosis prodrug isoniazid bound to activating peroxidases.
by: Metcalfe, C, et al.
Published: (2008)

CURRENT APPROACHES TO CONTROL OF ISONIAZID-RESISTANT TUBERCULOSIS
by: Vladimir Milanov, et al.
Published: (2022-10-01)

The use of isoniazid syrup for the prevention of tuberculosis in children.
by: Liliya Todoriko, et al.
Published: (2019-09-01)

Protocol for pragmatic randomized clinical trial to evaluate the completion of treatment of latent Mycobacterium tuberculosis infection with Isoniazid in the 300 mg formulation.
by: João Paulo Cola, et al.
Published: (2023-01-01)

Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis.
by: Roy Gerona, et al.
Published: (2016-01-01)

Publisher Correction: Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors
by: Edward Chia‑Cheng Lai, et al.
Published: (2021-10-01)

Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.
by: Andrew Kazibwe, et al.
Published: (2022-01-01)

Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand
by: Ajala Prommi, et al.
Published: (2024-03-01)